NEW YORK, June 10, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases,...
BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 18,166,667 shares of its common stock and pre-funded warrants to purchase up to 1,833,395 shares of its common stock (the “Offering”). The offering price of each share of common stock is $30.00. The offering price of each pre-funded warrant is $29.999, which represents the per share offering price for the common stock less the $0.001 per share exercise price for such pre-funded warrant. The gross proceeds from the Offering, before deducting underwriting discounts and commissions and offering-related expenses, are expected to be approximately $600 million. All of the shares and pre-funded warrants in the Offering are to be sold by Tango. The Offering is expected to close on or about June 11, 2026, subject to customary closing conditions. In addition, Tango has granted the underwriters a 30-day option to purchase up to an additional 3,000,009 shares of common stock at the public offering price, less the underwriting discount.
CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease, today announced the pricing of its upsized initial public offering of 33,500,000 shares of its common stock at a price to the public of $20.00 per share. In addition, Parabilis has granted the underwriters a 30-day option to buy an additional 5,025,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.
Incline Village, NV, June 09, 2026 (GLOBE NEWSWIRE) -- RMG ML Sports Holdings (the “Company”), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company and led by Chief Executive Officer, James Carpenter, and President and Chief Financial Officer, Douglas Horlick, today announced the pricing of its initial public offering of 20,000,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one right to receive one-eighth (1/8) of one Class A ordinary share upon the consummation of the Company’s initial business combination. The units are expected to trade on the Global Market tier of the Nasdaq Stock Market (“Nasdaq”) under the ticker symbol “SHOTU” beginning June 10, 2026. Once the securities comprising the units begin separate trading, the ordinary shares and the rights are expected to be traded on Nasdaq under the symbols “SHOT” and “SHOTR,” respectively.
HAMILTON, Bermuda, June 9, 2026 /PRNewswire/ -- Borr Drilling Limited (NYSE: BORR) (OSE: BORR) ("Borr Drilling" or the "Company") today announced the pricing terms of...
Los Angeles, CA, June 09, 2026 (GLOBE NEWSWIRE) -- Aperture AC (the “Company”) (Nasdaq: APURU) announced today that on June 10, 2026, the Company’s units will no longer trade, and that the Company’s Class A ordinary shares and rights, which together comprise the units, will commence trading separately. The Class A ordinary shares and rights will be listed on the Nasdaq Capital Market and trade with the ticker symbols “APUR” and “APURR”, respectively. This is a mandatory and automatic separation, and no action is required by the holders of units.
SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common...
/Not for distribution to U.S. news wire services or dissemination in the United States./TORONTO, June 8, 2026 /CNW/ - Apotex Health Corp. ("Apotex" or the...
New York, New York, June 08, 2026 (GLOBE NEWSWIRE) -- Ocean Capital Acquisition Corporation, a blank check company incorporated in the British Virgin Islands as an exempted company with limited liability (the “Company”), today announced the pricing of its initial public offering (the “IPO” or this “Offering”) of 10,000,000 units (the “Units”) at an offering price of $10.00 per Unit, with each Unit consisting of one ordinary share, one redeemable warrant, and one right to receive one ordinary share upon the consummation of an initial business combination. Each redeemable warrant entitles the holder thereof to purchase one ordinary share of the Company at a price of $11.50 per share, subject to certain adjustments.
New York, New York, June 08, 2026 (GLOBE NEWSWIRE) -- Snow Rothschild Acquisition Corp. (NASDAQ: ISNRU) (the “Company”) today announced the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit. Each unit issued in the offering consists of one Class A ordinary share of the Company and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. In connection with the offering, $10.00 per unit will be deposited into a trust account with Continental Stock Transfer & Trust acting as trustee. The Company’s units are expected to be listed on the Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “ISNRU” and are expected to begin trading on June 9, 2026. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “ISNR” and “ISNRW,” respectively. The closing of the offering is anticipated to take place on or about June 10, 2026, subject to customary closing conditions.
ZUG, Switzerland, June 08, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference.